Company intelligence / Profile preview
Five Eleven Pharma, Inc.
Philadelphia, Pennsylvania, United Statesfiveelevenpharma.com ↗
- Ownership
- Private
- Employees
- ~2
- Development stage
- Other
01
Overview
The company has several radiopharmaceutical products in development, with their lead candidate Gallium-68 P16-093 (targeting PSMA) in Phase 2 clinical trials for non-metastatic prostate cancer. They also have 68Ga-P15-041 in Phase 1 for prostatic cancer, [18F]P17-059 (targeting VMAT2) in Phase 1 for Parkinson's Disease, a FAP-α Imaging Agent in preclinical development for neoplasms, and [177Lu]Lu-P17-079 (targeting PSMA) in discovery phase for prostatic cancer.
- Therapeutic areas
- OncologyNeurology
- Modalities
- Diagnostic radiopharmaceuticalsRadionuclide Drug Conjugates (RDC)Small molecule drugsTherapeutic radiopharmaceuticalsChemical drugs
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Beijing Binpai Biotechnology Co., Ltd.
Beyond the preview
Go deeper on Five Eleven Pharma, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Five Eleven Pharma, Inc..